In vitro metabolism and in vivo pharmacokinetics of quinoline 3-carboxamide derivatives in various species

References

• Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde A, Astrom M, Gjorstrup P, Ekholm S. 1996. Linomide reduces the rate of active lesions in relapsing—remitting multiple sclerosis. Neurology 47:895–900.
   PubMed Web of Science ®Google Scholar
• Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, Aström, M, Hedlund G. 2002. The new orally active immunoregulator Laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 130:163–172.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Diab A, Michael L, Wahren B, Deng GM, Björk J, Hedlund G, Zhu J. 1998. Linomide suppresses acute experimental autoimmune encephalomyelitis in the Lewis rats by counteracting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. Journal of Neuroimmunology 85:146–154.
   PubMed Web of Science ®Google Scholar
• Ernster L, Siekevitz P, Palade GE. 1962. Enzyme—structure relationships in the endoplasmic reticulum of rat liver. Journal of Cell Biology 15:541–562.
   PubMed Web of Science ®Google Scholar
• Gross D, Weiss L, Reibstein I, Hedlund G, Dahlén E, Rapoport M, Slavin S. 2001. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus. International Immunopharmacology 1:1131–1139.
   PubMedGoogle Scholar
• Hedlund G, Link H, Zhu J, Xiao B. 2001. Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system. International Immunopharmacology 1:1123–1130.
   PubMedGoogle Scholar
• Jonsson S, Andersson G, Fex T, Fristedt T, Hedlund G, jansson K, Abramo L, Fritzson I, Pekarski O, Runstrom A, Sandin H, Thuvesson I, Björk A. 2004. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure—activity relationship. Journal of Medicinal Chemistry 47:2075–2088.
   PubMed Web of Science ®Google Scholar
• Karussis DM, Lehmann D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Ben Nun A, Kalland T, Abramsky O. 1993a. Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Annals of Neurology 34:654–660.
   PubMed Web of Science ®Google Scholar
• Karussis DM, Lehmann D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Kalland T, Abramsky O. 1993b. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline-3-carboxamide). Proceedings of the National Academy of Sciences, USA 90:6400–6404.
   PubMed Web of Science ®Google Scholar
• Karussis DM, Meiner Z, Lehman D, Schwartz A, Gomori M, Ovadia H, Mizrachi-Koll R, Gjorstrup P, Linde A, Abramsky O.1996. Treatment of secondary progressive multiple sclerosis with the immunomodulator Linomide: a double-blind placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47:341–346.
   PubMed Web of Science ®Google Scholar
• Lu AH, Lewin W. 1972. Partial purification of cytochromes P450 and P448 from rat liver microsomes. Biochemical and Biophysical Research Communication 46:1334–1339.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Koymans L, Kamataki T, Stegeman jj, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42.
   PubMedGoogle Scholar
• Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC, and The North American Linomide Investigators. 2000. Linomide in relapsing and secondary progressive MS. Part I: Trial design and clinical results. Neurology 54:1726–1733.
   Google Scholar
• Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T. 2004. Treatment with laquinimod reduces development of active MRI lesions in relapsing multiple sclerosis (submitted).
   Google Scholar
• SAS/STAT User's guide, Version 6, 4th edn, Vol. 1. Cary, NC: SAS Institute, Inc., 1989.
   Google Scholar
• Strandgárden K, Hoglund P, Gronquist L, Svensson L, Gunnarsson PO. 2000. Absorption and disposition including enterohepatic circulation of (14C) Roquinimex after oral administration to healthy volunteers. Biopharmaceutics and Drug Disposition 21:53–67.
   PubMed Web of Science ®Google Scholar
• Tan IL, Lycklama A, Nijeholt GJ, Polman CH, Ader HJ, Barkhof F, and The 95 Line 146/146 Study Group. 2000. Linomide in treatment of multiple sclerosis: MRI results from prematurely terminated phase III-trials. Multiple Sclerosis 6:99–104.
   PubMed Web of Science ®Google Scholar
• Tuvesson H, Hallin I, Persson R, Sparre B, Gunnarsson PO, Seidegird J. 2004. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism .of laquinimod, a novel immunomodulator (submitted).
   Google Scholar
• Tuvesson H, Strandgirden K, Nordle O, Gunnarsson PO, Seidegard J, Persson R. 2000a. Metabolism of roquinimex in mouse and rat: and in vitro/in vivo comparison. Xenobiotica 30:371–380.
   PubMed Web of Science ®Google Scholar
• Tuvesson H, Wienkers LC, Gunnarsson PO, Seidegárd J, Persson R. 2000b. Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Xenobiotica 30:905–914.
   PubMed Web of Science ®Google Scholar
• WinNonlin. 1997. Professional user's guide, ver. 1.5. Lexington: Scientific Consulting, Inc.
   Google Scholar
• Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjorstrup, P, Sullivan HC. 2000. Linomide in relapsing and secondary progressive MS: Part II: MRI results. MRI analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide investigators. Neurology 54:1734–1741.
   Google Scholar
• Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. 2004. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. Journal of Neuroimmunology 156:3–9.
   PubMed Web of Science ®Google Scholar